✨ Your Portfolio is fetched and updated from zerodha.
Small Pharmaceuticals

Bliss GVS Pharma Ltd.

BLISSGVS

Market Cap
₹1,642 Cr.
P/E
19.48

Bliss GVS Pharma Ltd.

  • Bliss GVS Pharma
  • Beta Drugs
  • Syncom Formulations
  • TJI Pharma
FAQs on Bliss GVS Pharma Ltd. Shareprice

Bliss GVS Pharma has given lower returns compared to its competitors.
Bliss GVS Pharma has grown at ~-0.59% over the last 7yrs while peers have grown at a median rate of 50.51%

Bliss GVS Pharma is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE.
Latest PE of Bliss GVS Pharma is 19.78, while 3 year average PE is 50.51.
Also latest EV/EBITDA of Bliss GVS Pharma is 12.04 while 3yr average is 8.61.

View FAQ's On Business
Growth Table
  • Bliss GVS Pharma Ltd.
  • Beta Drugs
  • Syncom Formulations
Balance Sheet
  • Bliss GVS Pharma Ltd.
  • Beta Drugs
  • Syncom Formulations
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Bliss GVS Pharma Ltd.
  • Beta Drugs
  • Syncom Formulations
Cash Flow
  • Bliss GVS Pharma Ltd.
  • Beta Drugs
  • Syncom Formulations
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Bliss GVS Pharma Ltd.
  • Beta Drugs
  • Syncom Formulations
Quarterly Results
  • Bliss GVS Pharma Ltd.
  • Beta Drugs
  • Syncom Formulations
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Bliss GVS Pharma Ltd. Financials

Balance sheet of Bliss GVS Pharma is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Bliss GVS Pharma is increasing.
Latest net debt of Bliss GVS Pharma is -₹142.33 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹343.36 Crs.

Yes, profit is increasing.
The profit of Bliss GVS Pharma is ₹90.25 Crs for TTM, ₹75.45 Crs for Mar 2024 and ₹70.86 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Bliss GVS Pharma latest dividend payout ratio is 6.94% and 3yr average dividend payout ratio is 16.25%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Accounts Receivable

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech